[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-dialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-dialysis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,86,112,134,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100621014","insights-into-the-continuous-renal-replacement-therapy-to-critical-ill-patients-100621014",false,"NCT07365111","Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients","Insights Into the Characteristics, Prescription and Delivery of Continuous Renal Replacement Therapy to Critical Ill Patients - The iCRRT Data Registry","iCRRT","Inclusion Criteria:\n\n1. Admission to an intensive care unit\n2. CRRT therapy\n\nExclusion Criteria:\n\n1. End-stage kidney disease\n2. CRRT \\\u003C24 hours","ALL",{"count":19,"type":20},100000,"ESTIMATED","90 Days","OBSERVATIONAL","This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide. The study aims to examine similarities and differences in CRRT practices and outcomes among critically ill adult patients across a global network of medical centers.\n\nThe goal is to develop a large, comprehensive repository of data on CRRT practices and outcomes. This repository will enable characterization of variation in standard CRRT practices across medical centers. Natural variability in practice patterns-both between and within centers-will provide an opportunity to compare outcomes associated with different approaches and to generate high-quality preliminary data to inform future interventional trials.\n\nPrimary Objective\n\n\\- To describe global patient characteristics, CRRT modalities, and clinical outcomes among patients receiving CRRT.\n\nSecondary Objectives\n\n* To compare clinical outcomes across geographic regions and CRRT modalities.\n* To identify patient-level and practice-level predictors of outcomes.\n* To assess the impact of comorbid conditions (e.g., diabetes mellitus) on CRRT outcomes.\n\nExploratory Objectives\n\n* To evaluate long-term renal outcomes and patient-reported quality of life.\n* To explore health economics and resource utilization related to CRRT.\n\nStudy Population All patients receiving CRRT as part of routine clinical care in the ICU at participating centers will be eligible for inclusion.\n\nData Collection The study will support an epidemiological assessment of patients undergoing CRRT, including, but not limited to, demographics, underlying disease states, severity of illness, physiological support, indications for CRRT, and clinical outcomes. Outcomes of interest include ICU and hospital mortality, ICU and hospital length of stay, and renal recovery.",[25,26,27,28],"Continuous Renal Replacement Therapy (CRRT)","Acute Kidney Injury","Renal Dialysis","Critical Illness",[30,31,26,32],"Continue Renal Replacement Therapy","Dialysis","Intensive Care Unit","NOT_YET_RECRUITING","2026-05-28",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":39,"type":20},"2026-07-01",{"date":41,"type":20},"2036-12-31",{"name":43,"class":44},"University of Alberta","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":45},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin","18 Years",{"count":56,"type":20},15,"INTERVENTIONAL",[59],"NA","People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[62,63,27,64,65,66],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease on Hemodialysis","Uremia; Chronic","Hemodialysis","Hemodiafiltration",[68,69,70,71,72,73,74,75,76],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":79,"type":37},"2026-03-24",{"date":81,"type":20},"2026-04",{"date":83,"type":20},"2029-12",{"name":85,"class":44},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100617000","machine-learning-and-artificial-intelligence-algorithms-to-optimize-the-performance-and-delivery-of-acute-dialysis-100617000","NCT07312929","Machine Learning and Artificial Intelligence Algorithms to Optimize the Performance and Delivery of Acute Dialysis","SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.","SMART DIALYSIS","Inclusion Criteria\n\nPatients admitted to an intensive care unit (ICU) who require acute renal replacement therapy, either intermittent or continuous.\n\nExclusion Criteria\n\nReceipt of renal replacement therapy for less than 24 hours.\n\nPre-existing end-stage kidney disease.",{"count":95,"type":20},7500,"SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.\n\nHypothesis:\n\nCan the investigators develop and implement Machine Learning and Artificial Intelligence Algorithms into Clinical Information Systems to Optimize the Prescription, Delivery, and Performance of Acute Dialysis?\n\nObjective(s):\n\n1. Identify variables surrounding identified Key Performance Indicators that may be used by Machine Learning and Artificial Intelligence algorithms to optimize the prescription and performance of acute dialysis.\n2. Develop Machine Learning and Artificial Intelligence algorithms to help guide the prescription and delivery of acute dialysis in the development of Clinical Decision Support tools and Best Practice Advisories and create a ML\u002FAI Augmented SMART DIALYSIS Digital Dashboard.\n3. Implement and evaluate the performance of the developed Machine Learning and Artificial Intelligence algorithms on patient-centered and health economic outcomes.\n4. Validate and benchmark the performance of the evaluated Machine Learning and Artificial Intelligence algorithms across multiple jurisdictions.",[27,98,99,100],"Renal Replacement Therapy","Renal Diseases","Quality Health Care",[31,102,103,104],"Articfical Inteligence","Key performance indicators","Machine Learning","2026-01-08",{"date":107,"type":37},"2026-01-12",{"date":36,"type":20},{"date":110,"type":20},"2031-06-30",{"name":43,"class":44},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100545059","prospective-multicentre-randomized-controlled-cross-over-study-on-the-safety-and-performance-of-the-biologic-fusion-option-of-dialogiq-compared-to-haemodialysis-without-biologic-fusion-in-hypotension-prone-patients-on-maintenance-haemodialysis-100545059","NCT06376968","Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis","Inclusion Criteria:\n\n* Male or female subjects ≥18 years of age\n* Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months\n* Dialysis frequency 3 x per week\n* Dialysis duration per session ≥ 4h\n* Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes\n* No residual renal function (definition: ≤100 ml urine\u002Fday) - changed to \"No to minimal residual renal function (definition: ≤ 300 ml\u002Fday)\" with Amendment 1 (CIP version 6)\n* Stable dry body weight for at least 4 weeks\n* Subjects who are willing to give a voluntary consent to participate in the study\n\nExclusion Criteria:\n\n* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)\n* Vascular access insufficiency (mean blood flow \\\u003C200ml\u002Fmin)\n* Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: \" Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles\" with Amendment 1 (CIP version 6)\n* Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)\n* Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period\n* Factors which may interfere with full participation in the trial\n* Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)\n* Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study",{"count":119,"type":20},56,[59],"The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:\n\n• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.\n\nA crossover design is used to compare treatments with or without the BioLogic Fusion function activated.",[27],"RECRUITING","2025-09-08",{"date":126,"type":37},"2025-09-12",{"date":128,"type":37},"2024-04-22",{"date":130,"type":20},"2027-06",{"name":132,"class":133},"B.Braun Avitum AG","INDUSTRY",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":57,"phases":146,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100605279","phase-4-levocarnitine-for-reducing-esa-requirements-in-hemodialysis-patients-with-renal-anemia-100605279","NCT07160452","Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia","Effect of Levocarnitine Injections on Reducing Erythropoietin-Stimulating Agent Requirements in Hemodialysis Patients With Renal Anemia","L-CAR-ESA","Inclusion Criteria:\n\n1. Both male and female patients\n2. Patients aged 20-60 years.\n3. Patients undergoing maintenance hemodialysis three times a week for at least six months\n4. Patients having renal anemia\n\nExclusion Criteria:\n\n1. Patients currently using any carnitine preparation as a supplement (to avoid confounding effects from additional carnitine intake).\n2. Patients on immunosuppressive drugs, steroids, or antibiotics (to avoid the influence of these medications on anemia and carnitine metabolism).\n3. Patients who have previously received levocarnitine in either oral or injected form (to eliminate any prior influence of levocarnitine on study outcomes).\n4. Patients with a history of blood transfusion within the past 6 months (to exclude the immediate impact of transfusions on hemoglobin levels and anemia management).\n5. Patients with acute inflammation (to prevent interference with study parameters as inflammation can affect anemia status).\n6. Patients with communication difficulties due to dementia or other factors (to ensure accurate symptom reporting and study adherence).","20 Years","60 Years",{"count":145,"type":20},94,[147],"PHASE4","Renal anemia is common in people receiving long-term hemodialysis and is usually treated with erythropoiesis-stimulating agents (ESAs). Some patients respond poorly and require high ESA doses, which increases treatment burden, cost, and potential side effects. Carnitine deficiency is frequent in hemodialysis because carnitine is lost during dialysis and its synthesis is reduced. Levocarnitine may improve red blood cell function and reduce the dose of ESA needed to maintain hemoglobin.\n\nThis single-center, randomized controlled trial will test whether adding intravenous levocarnitine to standard care reduces ESA requirements in adults on maintenance hemodialysis who have renal anemia. Ninety-four participants (age 20-60 years) on thrice-weekly hemodialysis for ≥6 months and with hemoglobin \\\u003C10 g\u002FdL will be randomly assigned (1:1) to:\n\nIntervention: Levocarnitine 1,000 mg IV three times per week, administered after each dialysis session, plus usual anemia care including ESA per unit protocol.\n\nControl: Usual anemia care including ESA per unit protocol without levocarnitine.\n\nParticipants will be followed for 6 months. Hemoglobin, hematocrit, ESA dose, and the erythropoietin responsiveness index (ERI = monthly ESA dose ÷ \\[dry weight × average hemoglobin\\]) will be recorded monthly.\n\nThe primary outcome is the ESA dose (units\u002Fweek) at month 6. Secondary outcomes include ERI and monthly changes in hemoglobin and hematocrit, along with routine safety monitoring. If levocarnitine lowers ESA needs, the findings may offer a cost-effective strategy to optimize anemia management in hemodialysis patients.",[150,151,152,27],"Anemia","Kidney Failure","End-Stage Renal Disease",[154,155,156,157,158],"Levocarnitine","L-carnitine","Erythropoiesis-Stimulating Agents","Erythropoietin Responsiveness Index","Hematocrit","2025-09-06",{"date":126,"type":37},{"date":162,"type":20},"2025-09-15",{"date":164,"type":20},"2026-03-15",{"name":166,"class":44},"Shaikh Zayed Hospital, Lahore",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":57,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100569283","impact-of-hospital-pharmacist-intervention-on-medication-management-in-dialysis-patients-100569283","NCT06692231","Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients","Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients After Assessment of Health Literacy Level","IPhaDia","Inclusion Criteria:\n\n* Patient over 18 years of age\n* On dialysis (peritoneal dialysis, hemodialysis) for at least 3 months\n* Prescription for at least 5 daily medications\n* Patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure.\n\nExclusion Criteria:\n\n* Patient does not speak and\u002For understand French\n* Patient's cognitive state does not permit an interview\n* Patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home)\n* Patient refusal",{"count":176,"type":20},70,[59],"The goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. In a first time, the health literacy level will be assed.\n\nThe main questions it aims to answer are:\n\nWhat is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? Does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? Researchers will compare a group with a pharmacist intervention VS a group without pharmacist intervention for dialysis patients.",[27,180,181],"Health Literacy Level","Kidney Disease, Chronic",[183,184],"clinical pharmacist","end stage renal disease","2024-11-14",{"date":187,"type":37},"2024-11-18",{"date":189,"type":20},"2024-11-15",{"date":191,"type":20},"2027-02-28",{"name":193,"class":44},"Centre Hospitalier de Vichy",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":57,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100559799","the-effect-of-active-exercise-on-maintenance-haemodialysis-patients-100559799","NCT06568835","The Effect of Active Exercise on Maintenance Haemodialysis Patients","Effect of Active Exercise on Nutritional and Inflammatory Status, Muscle Metabolism and Cardiovascular Events in Maintenance Haemodialysis Patients","Inclusion Criteria:\n\n* MHD more than 3 months, 3 times per week, 3-4h each time;\n* Urea clearance index (Kt\u002FV) \\>1.2;\n* Stable condition, no serious infection, tumour and cardiovascular disease;\n* Willing to join the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Combined with serious heart and lung disease: such as repeated heart failure, severe arrhythmia, unstable angina pectoris, severe pericardial effusion, severe heart valve disease, hypertrophic cardiomyopathy, aortic coarctation, severe emphysema, pulmonary heart disease, severe pulmonary hypertension (average pressure of the pulmonary artery \\> 55mmHg), etc.;\n* Combined with chronic joints, muscles, or vascular disease can not be or is not suitable for regular exercise, such as cerebrovascular disease; combined chronic joint, muscle or vascular disease can not or are not suitable for regular exercise, such as cerebrovascular disease sequelae, serious lower limb joint damage, severe myopathy, deep vein thrombosis, etc.;\n* unwilling to cooperate with the movement of people","75 Years",{"count":203,"type":20},200,[59],"The goal of this clinical trial is to discuss the effects of physical activity on nutrition, inflammation, muscle metabolism, and the occurrence of cardiovascular and cerebrovascular events in patients with maintenance haemodialysis. The main question it aims to answer is: can exercise improve nutritional and inflammatory status, enhance muscle strength, and reduce the incidence of cardiovascular and cerebrovascular events in patients with maintenance haemodialysis.\n\nResearchers will compared active exercise group to conventional treatment group to see the impact of exercise on maintenance haemodialysis patients.\n\nParticipants will:\n\nChoose low-intensity aerobic exercise workouts such as walking (no less than 8,000 steps per day) or jogging, swimming, Tai Chi, etc., according to their individual conditions, for no less than 30 minutes at a time, at least 3 times per week, and the intensity of the exercise should be based on an RPE score of 12 to 16.",[27],[208,209,210,211],"Exercise","Inflammation","Nutrition","Muscular Atrophy","2024-08-21",{"date":214,"type":37},"2024-08-23",{"date":216,"type":37},"2024-01-01",{"date":218,"type":20},"2025-07-01",{"name":220,"class":44},"Yunfeng Xia"]